Expression of Programmed Cell Death Ligand in Cutaneous Squamous Cell Carcinoma and Treatment of Locally Advanced Disease With Pembrolizumab
Sign Up to like & getrecommendations! Published in 2017 at "JAMA Dermatology"
DOI: 10.1001/jamadermatol.2016.5118
Abstract: Importance Limited therapies are available in patients with inoperable locally advanced cutaneous squamous cell carcinoma (cSCC). Objective To determine the efficacy of programmed cell death 1 receptor (PD-1) inhibitors in locally advanced cSCC. Design, Setting,… read more here.
Keywords: treatment; expression; pembrolizumab; locally advanced ... See more keywords
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2020 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2019.5570
Abstract: Importance Whether immune-related adverse events (irAEs) indicate drug activity in patients treated with immune checkpoint inhibitors remains unknown. Objective To investigate the association between irAEs and recurrence-free survival (RFS) in the double-blind EORTC 1325/KEYNOTE-054 clinical… read more here.
Keywords: melanoma; arm; stage iii; recurrence ... See more keywords
Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2022.5486
Abstract: Importance A key issue for the adjuvant treatment of patients with melanoma is the assessment of the effect of treatment on relapse, survival, and quality of life (QOL). Objective To compare QOL in patients with… read more here.
Keywords: adjuvant pembrolizumab; trial; fact; hdi ... See more keywords
Genome‐wide aneuploidy detected by mFast‐SeqS in circulating cell‐free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Oncology"
DOI: 10.1002/1878-0261.13196
Abstract: Second‐line treatment with immune checkpoint inhibition in patients with metastatic urothelial cancer (mUC) has a low success rate (~ 20%). Circulating tumour‐derived DNA (ctDNA) levels may guide patient stratification, provided that an affordable and robust assay… read more here.
Keywords: mfast seqs; urothelial cancer; seqs; response ... See more keywords
Exploiting the Innate Plasticity of the Programmed Cell Death‐1 (PD1) Receptor to Design Pembrolizumab H3 Loop Mimics **
Sign Up to like & getrecommendations! Published in 2022 at "ChemBioChem"
DOI: 10.1002/cbic.202200449
Abstract: Checkpoint blockade of the immunoreceptor programmed cell death‐1 (PD1) with its ligand‐1 (PDL1) by monoclonal antibodies such as pembrolizumab provided compelling clinical results in various cancer types, yet the molecular mechanism by which this drug… read more here.
Keywords: cell death; death pd1; innate plasticity; pd1 ... See more keywords
Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD‐L1‐positive locally advanced or metastatic non–small‐cell lung cancer: KEYNOTE‐042 China Study
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Cancer"
DOI: 10.1002/ijc.33399
Abstract: In the global KEYNOTE‐042 study (Clinicaltrials.gov, NCT02220894), pembrolizumab significantly improved overall survival (OS) vs chemotherapy in patients with previously untreated programmed death ligand 1 (PD‐L1)‐positive locally advanced/metastatic non–small‐cell lung cancer (NSCLC) without EGFR/ALK alterations. We… read more here.
Keywords: chemotherapy; advanced metastatic; study; keynote 042 ... See more keywords
Therapy with pembrolizumab in treatment‐naïve patients with nonmetastatic, mismatch repair deficient colorectal cancer
Sign Up to like & getrecommendations! Published in 2023 at "International Journal of Cancer"
DOI: 10.1002/ijc.34420
Abstract: Therapy with immune checkpoint inhibitors (ICI) is effective in patients with metastatic mismatch‐repair deficient (dMMR) colorectal cancer (CRC); however, data on treatment with neoadjuvant ICI in patients with locally advanced CRC are limited. From March… read more here.
Keywords: mismatch repair; therapy; colorectal cancer; treatment ... See more keywords
[Immunotherapy for head and neck cancer : Highlights of the 2019 ASCO Annual Meeting].
Sign Up to like & getrecommendations! Published in 2019 at "HNO"
DOI: 10.1007/s00106-019-00761-8
Abstract: BACKGROUND In the field of immunotherapy of head and neck squamous cell carcinoma (HNSCC), a high level of study activity can still be observed. The results of the Keynote-048 study on first-line therapy with pembrolizumab were… read more here.
Keywords: meeting; immunotherapy head; study; pembrolizumab ... See more keywords
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Immunology, Immunotherapy"
DOI: 10.1007/s00262-020-02613-9
Abstract: Background Single-agent pembrolizumab represents the standard first-line option for metastatic non-small-cell lung cancer (NSCLC) patients with a PD-L1 (programmed death-ligand 1) expression of ≥ 50%. Methods We conducted a multicenter retrospective study aimed at evaluating the… read more here.
Keywords: first line; clinicopathologic correlates; bone; expression ... See more keywords
Low-dose pembrolizumab for relapsed/refractory Hodgkin lymphoma: high efficacy with minimal toxicity
Sign Up to like & getrecommendations! Published in 2017 at "Annals of Hematology"
DOI: 10.1007/s00277-017-2931-z
Abstract: Five patients with refractory/relapsed classical Hodgkin lymphoma (cHL), four having failed multiple lines of chemotherapy and brentuximab vedotin, were treated with low-dose pembrolizumab (median dose 100 mg, range: 100–200 mg, every 3 weeks). Complete response (CR) was achieved… read more here.
Keywords: minimal toxicity; low dose; hodgkin lymphoma; pembrolizumab ... See more keywords
Susac’s syndrome as an immune-related adverse event after pembrolizumab: a case report
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Neurology"
DOI: 10.1007/s00415-019-09587-4
Abstract: Immune checkpoint inhibitors are increasingly used in cancer treatment and have a significant impact on survival [1]. Pembrolizumab is a recombinant monoclonal antibody that blocks the programmed death-1 (PD-1) receptor, which is an inhibitor of… read more here.
Keywords: response; immune related; susac syndrome; case ... See more keywords